Trulieve Cannabis Corp.

https://www.trulieve.com/

Trulieve Cannabis Corp. is a leading vertically integrated cannabis company in the U.S., focused on cultivating, producing, and distributing cannabis products. The company's mission is to provide the highest quality cannabis products and the best patient experience, aiming to expand access to cannabis. Trulieve's corporate headquarters are located in Tallahassee, Florida, while the company is incorporated in British Columbia, Canada.

Trulieve offers a comprehensive range of cannabis products, including flower, edibles, concentrates, vapes, topicals, and accessories. The company has developed a product line with a strong medical focus, manufacturing over 700 SKUs in Florida, and features in-house brands such as Muse™, Sweet Talk™, Momenta™, and Cultivar Collection™. Trulieve operates dispensaries and provides direct-to-patient home delivery services, serving both medical and adult-use cannabis markets across multiple states. The company has established hubs in the Northeast, Southeast, and Southwest, with significant operations in cornerstone markets like Arizona, Florida, Ohio, and Pennsylvania.

Under the leadership of CEO Kim Rivers, Trulieve maintains its position as an industry-leading multi-state operator and one of the largest cannabis companies in the U.S. The company employs a hub-based strategy for expansion and market penetration. In recent news, Trulieve filed applications with the U.S. Drug Enforcement Administration (DEA) for the registration of state-licensed medical marijuana operations, following the reclassification of medical marijuana to Schedule III. The company reported full-year 2025 revenue of $1.2 billion.

Latest updates

Trulieve Seeks DEA Registration Amid Cannabis Rescheduling

Event summary

  • Trulieve Cannabis Corp. has filed applications with the DEA for registration of its state-licensed medical marijuana operations.
  • The applications are being submitted under an expedited registration pathway created following the rescheduling of medical marijuana to Schedule III.
  • The expedited process grants approval within 60 days unless the DEA notifies applicants otherwise.
  • Trulieve operates over 200 dispensaries focused solely on medical patients.

The big picture

The rescheduling of medical marijuana to Schedule III represents a significant shift in U.S. cannabis policy, opening up new avenues for research, investment, and potentially interstate commerce. Trulieve's proactive pursuit of DEA registration positions the company to capitalize on this change, but the expedited process also creates a compressed timeline and increased scrutiny. The move underscores the ongoing tension between state-level legalization and the federal government's regulatory framework.

What we're watching

Regulatory Approval
The DEA's timeline for processing Trulieve's application will be critical; any delays could impact near-term revenue projections and operational planning.
Competitive Landscape
The expedited registration process creates a first-mover advantage for Trulieve, but other state-licensed operators will likely follow suit, potentially intensifying competition for market share.
Federal Policy
While Schedule III rescheduling is a positive development, the long-term impact on Trulieve's business hinges on the broader trajectory of federal cannabis policy and potential for further reform.

Trump Administration Reschedules Marijuana, Removing 280E Tax Burden

Event summary

  • The U.S. Trump Administration has rescheduled medical marijuana to Schedule III under the Controlled Substances Act.
  • This reclassification, finalized April 23, 2026, follows a rulemaking process initiated in 2024.
  • The move removes Section 280E, the punitive tax burden previously applied to Schedule I and II substances.
  • The rescheduling allows for expanded medical research utilizing products already available through state-licensed operators.
  • The Attorney General initiated a further rulemaking process, anticipating an expedited timeline and a hearing this summer.

The big picture

The rescheduling represents a significant shift in federal cannabis policy, potentially unlocking substantial research and financial benefits for companies like Trulieve. While not legalization, this move aligns federal law more closely with state-level practices and creates a more favorable operating environment. The ongoing rulemaking process suggests further policy adjustments are likely, creating both opportunities and uncertainties for the industry.

What we're watching

Regulatory Headwinds
The expedited rulemaking process announced alongside the rescheduling carries uncertainty; the summer hearing will be a key indicator of the final scope of changes.
Research Impact
The extent to which increased research funding and clinical trials translate into tangible product innovation and market expansion for Trulieve remains to be seen.
Financial Impact
The removal of Section 280E will improve Trulieve’s profitability, but the magnitude of the impact will depend on the company’s current tax burden and overall financial health.

Trulieve Expands Tallahassee Footprint with Third Dispensary

Event summary

  • Trulieve Cannabis Corp. is opening its third dispensary in Tallahassee, Florida, located at 5138 Thomasville Road, Suite 1.
  • The grand opening celebration is scheduled for April 20, 2026, featuring promotional offers.
  • The new location will offer Trulieve's in-house brands (Co2lors, Cultivar Collection, etc.) and products from partner brands.
  • The dispensary will operate from 9 a.m. to 8:45 p.m. Monday-Saturday and 10 a.m. to 8 p.m. on Sundays.

The big picture

Trulieve's continued expansion in Florida, a cornerstone market, underscores its commitment to dominating the state's medical cannabis landscape. This move, while seemingly incremental, contributes to Trulieve's broader hub-and-spoke strategy aimed at consolidating market position across key states. The company's reliance on exclusive partnerships for product distribution highlights the importance of maintaining strong vendor relationships for competitive differentiation.

What we're watching

Market Saturation
The concentration of Trulieve dispensaries in Tallahassee raises questions about market saturation and potential cannibalization of existing locations, requiring careful monitoring of sales performance across the network.
Competitive Response
Other cannabis operators in Florida will likely observe Trulieve’s expansion and may respond with their own store openings or promotional activities, intensifying competition for market share.
Patient Acquisition
The effectiveness of the grand opening promotions and ongoing discounts (veteran and new customer) will be a key indicator of Trulieve’s ability to acquire new registered medical cannabis patients in the Tallahassee area.

Trulieve Expands Florida Footprint with Boca Raton Dispensary

Event summary

  • Trulieve Cannabis Corp. is opening a new medical cannabis dispensary in Boca Raton, Florida, located at 9293 Glades Road.
  • The grand opening celebration is scheduled for Friday, April 24, 2026.
  • The dispensary will operate from 9 a.m. to 8:45 p.m. Monday-Saturday and 10 a.m. to 8 p.m. on Sundays.
  • The location will offer Trulieve's in-house brands and products from partner companies, exclusively available in Florida.

The big picture

Trulieve's continued expansion in Florida, a cornerstone market, underscores its commitment to consolidating its position in the state's medical cannabis industry. This move, while expanding reach, also highlights the increasing competition within Florida's regulated cannabis market and the need for Trulieve to differentiate its offerings. The company's focus on exclusive partnerships suggests a strategy to build brand loyalty and control product distribution, but also introduces potential vulnerabilities.

What we're watching

Market Saturation
The density of Trulieve's Florida dispensary network raises questions about the sustainability of current sales per location and potential cannibalization as the market matures.
Partner Dependency
Trulieve's reliance on exclusive partnerships for product offerings creates a risk if those relationships are disrupted or competitors secure similar deals.
Regulatory Risk
Continued expansion is contingent on favorable regulatory developments in Florida and potential shifts in state-level cannabis policy.

Trulieve Expands Florida Footprint with Lutz Dispensary Opening

Event summary

  • Trulieve Cannabis Corp. is opening a new medical cannabis dispensary in Lutz, Florida, on April 11, 2026.
  • A grand opening celebration is scheduled for April 24, 2026, featuring promotional offers.
  • The Lutz dispensary will operate from 9:00 AM to 8:45 PM Monday-Saturday and 10:00 AM to 8:00 PM on Sundays.
  • The location will carry Trulieve’s in-house brands (Co2lors, Cultivar Collection, etc.) and products from partner brands.

The big picture

Trulieve's expansion into Lutz represents a continued effort to solidify its dominance in the Florida medical cannabis market, a cornerstone of its broader multi-state operations. This move, while seemingly incremental, underscores the company's strategy of localized market penetration. The company's focus on exclusive partnerships highlights the importance of brand differentiation in a rapidly evolving and increasingly competitive landscape.

What we're watching

Market Saturation
The continued expansion of Trulieve’s Florida dispensary network may face headwinds as the market matures and competition intensifies, potentially impacting margins.
Regulatory Risk
Changes in Florida’s medical cannabis regulations, particularly regarding licensing or product restrictions, could significantly impact Trulieve’s operational flexibility and profitability.
Brand Loyalty
The reliance on both Trulieve’s in-house brands and partner products necessitates careful management of brand perception and exclusivity agreements to maintain customer loyalty.

Trulieve Expands Florida Retail Footprint with DeLand Dispensary

Event summary

  • Trulieve Cannabis Corp. is opening a new medical cannabis dispensary in DeLand, Florida, located at 1329 North Woodland Boulevard.
  • The grand opening celebration is scheduled for Friday, March 20, 2026.
  • The dispensary will operate from 9 a.m. to 8:45 p.m. Monday through Saturday and 10 a.m. to 8 p.m. on Sundays.
  • The location will offer Trulieve's in-house brands (Co2lors, Cultivar Collection, etc.) and partner brands exclusively available in Florida.

The big picture

Trulieve's continued expansion in Florida, a key market for medical cannabis, underscores its hub-and-spoke distribution strategy. This expansion, while demonstrating confidence in the Florida market, also highlights the increasing competition within the state's cannabis sector. The company's ability to maintain profitability amidst growing competition and potential regulatory shifts will be crucial for sustained growth.

What we're watching

Market Saturation
The increasing density of dispensaries in Florida could intensify competition and pressure margins, requiring Trulieve to differentiate through service or product offerings.
Regulatory Risk
Changes to Florida’s medical cannabis regulations, particularly regarding licensing or product restrictions, could impact the profitability of the DeLand location and Trulieve’s broader operations.
Customer Loyalty
The effectiveness of Trulieve’s new customer discounts and veteran programs in driving long-term loyalty and repeat business will be a key indicator of the dispensary’s success.

Trulieve Expands Florida Footprint with Lake Wales Dispensary

Event summary

  • Trulieve Cannabis Corp. opened a new medical cannabis dispensary in Lake Wales, Florida, on March 11, 2026.
  • The dispensary is located at 1341 State Road 60 E and will operate seven days a week.
  • The location will offer Trulieve's in-house brands (Co2lors, Cultivar Collection, etc.) and products from partner brands.
  • Trulieve is offering a 60% discount to first-time customers and a 20% discount to veterans at all Florida locations.

The big picture

Trulieve’s expansion into Lake Wales underscores the company’s ongoing strategy to solidify its dominance in the Florida medical cannabis market. This move, coupled with its hub strategy, aims to capture a larger share of a rapidly growing market, but also highlights the increasing competition within the sector. The company's focus on exclusive partnerships suggests a bet on niche brand appeal, which carries both opportunity and risk.

What we're watching

Market Saturation
The continued expansion in Florida, while positive in the short term, raises questions about the long-term sustainability of Trulieve’s market share as competition intensifies.
Brand Loyalty
The reliance on exclusive partnerships with smaller brands could limit Trulieve’s ability to adapt if consumer preferences shift towards larger, more established players.
Regulatory Risk
Changes to Florida’s medical cannabis regulations, particularly regarding licensing or product restrictions, could disproportionately impact Trulieve’s established retail network.

Trulieve Posts Record Cash Flow, Restructures Debt Amid Regulatory Shifts

Event summary

  • Trulieve Cannabis Corp. reported full-year 2025 revenue of $1.2 billion and a 60% gross margin.
  • The company generated record 2025 cash flow from operations of $273 million and free cash flow of $229 million.
  • Trulieve redeemed $368 million of senior secured notes due 2026 and closed a $140 million private placement of senior secured notes due 2030.
  • The company received conditional approval for a Dispensing Organization license under the Texas Compassionate Use Program.

The big picture

Trulieve’s strong financial performance and debt restructuring demonstrate a focus on operational efficiency and financial stability within a rapidly evolving cannabis landscape. The conditional Texas license represents a strategic bet on future growth, but also introduces regulatory and competitive risks. The company’s reliance on retail sales (94% of revenue) highlights its vulnerability to shifts in consumer behavior and state-level regulations.

What we're watching

Regulatory Headwinds
The pace of federal rescheduling will significantly impact Trulieve’s expansion strategy and ability to capitalize on new market opportunities, potentially accelerating competition.
Texas Expansion
The success of Trulieve’s Texas license hinges on navigating the state’s regulatory framework and establishing a competitive position against existing operators.
Debt Sustainability
Trulieve’s ability to service its debt obligations, particularly the newly issued notes, will depend on sustained revenue growth and operational efficiency improvements.

Trulieve Secures $200 Million in Senior Debt Financing

Event summary

  • Trulieve Cannabis Corp. completed a second tranche of a private placement, raising $60 million in senior secured notes.
  • The total notes issued now amount to $200 million, with a 10.5% interest rate and due in 2030.
  • The notes were issued at a price of $1,000 plus accrued interest, totaling $12.37 per $1,000 principal.
  • Proceeds will be used for capital expenditures and general corporate purposes.
  • The notes are subject to a four-month Canadian statutory hold period before listing on the Canadian Securities Exchange (CSE).

The big picture

Trulieve's aggressive debt financing strategy signals a continued focus on expansion and market share capture within the competitive U.S. cannabis landscape. The $200 million raise provides significant capital for strategic initiatives, but also increases financial risk and dependence on future profitability. This move is consistent with a broader trend of cannabis companies leveraging debt to fuel growth in anticipation of potential federal regulatory changes.

What we're watching

Financial Leverage
The increased debt load will put pressure on Trulieve’s profitability and require careful management of capital expenditures to avoid covenant breaches.
CSE Listing
The delay in listing the notes on the CSE could impact investor sentiment and liquidity, particularly if regulatory hurdles arise.
Capital Allocation
The effectiveness of Trulieve’s capital expenditures in driving revenue growth and market share gains will be crucial to justifying the increased debt burden.

Trulieve Expands Florida Footprint with Fort Myers Dispensary

Event summary

  • Trulieve Cannabis Corp. is opening a new medical cannabis dispensary in Fort Myers, Florida, located at 17274 San Carlos Boulevard.
  • The grand opening celebration is scheduled for Friday, January 30, 2026, featuring discounts and giveaways.
  • The dispensary will operate from 9 a.m. to 8:45 p.m. Monday through Saturday and 10 a.m. to 8 p.m. on Sundays.
  • The location will offer Trulieve's in-house brands (Alchemy, Co2lors, etc.) and products from partner brands.

The big picture

Trulieve's continued expansion within Florida, a key market for medical cannabis, underscores the company's commitment to consolidating its position in the state. This move, while seemingly incremental, contributes to Trulieve's broader hub-and-spoke distribution strategy aimed at scaling operations across multiple states. The company's focus on patient access and affordability aligns with the ongoing trend of broader cannabis legalization and normalization.

What we're watching

Market Saturation
The increasing density of dispensaries in Florida may intensify competition and pressure margins, requiring Trulieve to differentiate through service or product offerings.
Regulatory Risk
Changes in Florida's medical cannabis regulations, particularly regarding licensing or product restrictions, could significantly impact Trulieve's operational flexibility and profitability.
Brand Loyalty
The reliance on partner brands for product variety exposes Trulieve to potential supply chain disruptions or shifts in consumer preference away from those brands.

Trump Administration Reschedules Marijuana, Removing 280E Tax Burden

Event summary

  • The Trump Administration reclassified marijuana from Schedule III under the Controlled Substances Act on December 18, 2025.
  • This reclassification does not legalize marijuana but removes the Section 280E tax burden.
  • The change allows for expanded medical marijuana research within the United States.
  • Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) publicly applauded the decision.

The big picture

The rescheduling of marijuana to Schedule III represents a significant, albeit limited, step towards broader cannabis reform in the United States. While it doesn't legalize the substance, the removal of the 280E tax burden provides a substantial financial boost to state-legal operators like Trulieve, potentially improving margins and enabling increased investment. The move also signals a shift in federal policy, albeit under a specific administration, and could spur further legislative and regulatory changes in the years ahead.

What we're watching

Financial Impact
The extent of Trulieve’s financial benefit from the removal of Section 280E will depend on its current profitability and reinvestment strategy, and may not be immediately apparent in earnings reports.
Research Velocity
The speed at which American universities and companies capitalize on the eased research restrictions will determine the long-term impact on product development and market differentiation within the cannabis sector.
Political Risk
Future administrations could reverse this rescheduling, creating ongoing uncertainty for cannabis operators and highlighting the vulnerability of the industry to political shifts.

Trulieve Expands Ohio Footprint via Licensing Deal in Findlay

Event summary

  • Trulieve Cannabis Corp. opened a new dispensary in Findlay, Ohio, on December 15, 2025.
  • Harvest Grows LLC is operating the dispensary under a licensing agreement with Trulieve.
  • This is Harvest Grows' third Trulieve-branded dispensary in Ohio, complementing Trulieve's existing owned locations.
  • The new dispensary will offer a wide range of cannabis products, including Trulieve's in-house brands Modern Flower and R.O.

The big picture

Trulieve’s expansion into Findlay, Ohio, represents a continued effort to build out its retail network through a combination of owned and licensed dispensaries. This strategy allows for faster market penetration but introduces complexities in brand control and operational consistency. The Ohio market is relatively new for adult-use cannabis, presenting both opportunities and challenges for Trulieve as it seeks to solidify its position within the state.

What we're watching

Franchise Model
The reliance on licensing agreements, as seen with Harvest Grows, introduces potential operational and brand consistency risks that Trulieve will need to manage to maintain its reputation.
Ohio Market
The success of this expansion hinges on the continued maturation of Ohio’s adult-use cannabis market and Trulieve's ability to capture market share amidst increasing competition.
Licensing Sustainability
The long-term viability of Trulieve’s licensing model will depend on its ability to attract and retain qualified partners like Harvest Grows, and the financial terms of those agreements.
CID: 383